Arvest Trust Co. N A Has $13.93 Million Stake in Johnson & Johnson (NYSE:JNJ)

Arvest Trust Co. N A lowered its stake in Johnson & Johnson (NYSE:JNJ) by 4.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 95,328 shares of the company’s stock after selling 4,064 shares during the period. Arvest Trust Co. N A’s holdings in Johnson & Johnson were worth $13,933,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in JNJ. Edgestream Partners L.P. boosted its stake in Johnson & Johnson by 132.9% in the 2nd quarter. Edgestream Partners L.P. now owns 71,787 shares of the company’s stock valued at $10,492,000 after purchasing an additional 40,966 shares during the period. Excalibur Management Corp lifted its position in Johnson & Johnson by 1.6% during the second quarter. Excalibur Management Corp now owns 40,514 shares of the company’s stock worth $5,921,000 after purchasing an additional 629 shares during the period. Luts & Greenleigh Group Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $1,131,000. Wulff Hansen & CO. increased its stake in shares of Johnson & Johnson by 14,424.6% in the 2nd quarter. Wulff Hansen & CO. now owns 1,625,299 shares of the company’s stock valued at $237,554,000 after purchasing an additional 1,614,109 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its position in Johnson & Johnson by 82.8% in the second quarter. Citizens Financial Group Inc. RI now owns 180,501 shares of the company’s stock valued at $26,382,000 after acquiring an additional 81,780 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $167.02 on Tuesday. The business has a 50-day moving average price of $159.98 and a two-hundred day moving average price of $153.98. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $401.96 billion, a P/E ratio of 10.41, a PEG ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the firm posted $2.80 earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is presently 30.92%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.